Abstract: The present invention relates to compounds and methods for treating retroviral infections and/or Hepatitis B viral infections. Some compounds of the invention are described by Formula I: or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.

Abstract: Disclosed are inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors are improved over those in the prior art by selection of particular classes of side chains in the P1 and/or P2 position of the inhibitor. The inhibitors can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.

Abstract: The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The present invention provides a method for treating irritable bowel syndrome (IBS) in a subject in need thereof. The treatment can include administering about 550 mg of rifaximin three times per day and about 500 mg of neomycin two times per day for 14 days to the subject to treat the IBS. In certain embodiments, the IBS is constipation predominant IBS (C-IBS).

Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: Present invention relates to a composition comprising novel bioactive compound obtained from oil palm based materials and the method of isolating bioactive compound thereof, wherein said compound is an indolacetic acid derivative. The compound is having at least one variation of moiety.

Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.

Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

Abstract: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.

Abstract: The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.

Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.

Abstract: The present disclosure generally relates to a bathwater additive which renders the bathwater viscous and slippery.

Abstract: The present invention relates to a composition for dispersing or hydrating mucus, which comprises poly-gamma-glutamic acid, a biocompatible natural polymer, and more particularly, to a composition for treating mucus hypersecretory disease, which comprises poly-gamma-glutamic acid or poly-gamma-glutamic acid nanogels. The composition according to the present invention is effective in treating mucus-related diseases by effectively dispersing and hydrating mucus which is excessively secreted in vivo and highly sticky.

Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m, and used for treating patients, for example, patients with hyperphosphatemia.

Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin.

Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The invention relates to compositions and methods for Inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention, and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) citrate.

Abstract: Surface-modified heavy metal nanoparticles, including a heavy metal core and a coating layer, the coating layer having at least one ligand, conjugated to polyethylene glycol, the at least one ligand is selected from N-acetyl cysteine, albumin, cysteine, methionine, glutathione, amino thiols, thio-carboxylic acids, ammonia, amines, diamines or any combination thereof. Compositions including surface-modified heavy metal nanoparticles and uses thereof in treatment and diagnosis of various conditions.

Abstract: The present invention provides compositions of therapeutic agents and methods of use for reducing and/or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae.

Abstract: The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.

Abstract: A method of treating gum disease while healing the wound in the periodontium using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate the periodontium to regenerate and heal its wound when used with substrates, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light circumferentially around the tooth vertically and horizontally throughout the sulcus with intermittent stops to control tissue temperature and placing substrates in the sulcus prior to blood clot formation; followed by RF treatment of the sulcus by placing the RF headpiece tips perpendicular to the sulcus to receive RF current which further penetrates the wound site.

Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction.

Abstract: The present invention concerns the field of nutritional compositions and concerns a nutritional composition, especially an infant formula containing whey protein/milk protein concentrate solids rich in phospholipids, rich in MFGM for use in the prophylaxis and prevention of infectious morbidity, especially otitis. At the same time the use of antipyretics has diminished.

Abstract: The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation.

Abstract: The present disclosure provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor.

Abstract: The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.

Abstract: The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration and diafiltration. The exosome formulations can be suitable for administration to a human.

Abstract: Methods for the extraction and processing of umbilical stem cells for therapeutic and diagnostic purposes are disclosed. The methods provide high regenerative cell numbers and high cell viability. Further, the methods do not require culturing the cells in serum or growth factors.

Abstract: Methods and compositions for treating ophthalmic disease, promoting development of functional neuronal synapses and improving neuronal outgrowth using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed. Trophic factors and other agents secreted by the cells that promote synapse formation and neuronal growth are also disclosed.

Abstract: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.

Abstract: Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: Compositions include probiotic microorganisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system.

Abstract: A method for optimizing the therapeutic effects provided by CBD on the one hand, and the psychoactive effects provided by THC on the other hand, in a sublingual medicament, the method includes the steps of obtaining a concentrated extract of cannabis in which the concentration of CBD is known and the concentration of THC is known, formulating a hydrophilic mixture containing ingredients such as sugar, corn syrup, xylitol, purified water, organic flavorings, coconut oil, and concentrated extract of cannabis, wherein the amount of CBD is as high as possible and where the amount of THC is precisely controlled, forming lozenges, and administering the medicament.

Abstract: A cannabinoid enriched alcohol composition for human consumption and method of manufacture for the composition are disclosed. The composition includes by weight about ninety-nine point nine-two percent (99.92%) ethanol in a liquid state and by weight about zero point zero eight percent (0.08%) cannabinoid in a liquid state. The composition is made by providing the ethanol in a liquid state and by providing the cannabinoid in the form of a cannabidiol oil in a liquid state, further a next step of combining the ethanol and the cannabidiol oil forming an initial mixture and agitating the initial mixture until the cannabidiol oil and the ethanol are in a substantially emulsified state with one another in a liquid state forming a completed mixture.

Abstract: The present invention provides a method of using a plant extract or active fraction thereof for inhibiting an herpes simplex virus (HSV) infection, wherein the plant is a: Cornus species; Achillea species; Trifolium species; Trillium species; and/or Plantago species. The present invention also provides plant extracts, active fractions, and compositions kits comprising same.

Abstract: Provided herein are plant based formulations for the prevention and management of diabetic vascular complication The formulation include hydro-alcoholic extract of Berberis Aristata, Trigonella foenum-graceum and Salacia parviflora in an effective dose. Also provided herein are methods of using such formulations.

Abstract: Provided herein are anti depressant and anxiolytic herbal formulations including: 225-450 mg of Nyctanthes arbortristis, 250-550 mg Ocimum tenuiflorum, 200-450 mg Hippophae salcifolia, and optionally additives selected from minerals, vitamins, salt, filler and binder. Also provided are methods of making such formulations and methods of using such formulations for treating or improving brain function.

Abstract: Improved processes for extracting polyphenols and/or flavonoids from citrus peels are provided that comprise 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel using a basic solution of pH greater than 7 and less than 12. Such processes serve to increase the efficiency of extraction of the polyphenols and/or flavonoids. In preferred embodiments, the flavonoids extracted include hesperidin and narirutin. These extracts are useful in the preparation of anti-inflammatory medicaments for the treatment of chronic inflammatory disorders such as inflammatory bowel disease, Crohn's disease, irritable bowel syndrome (IBS), and multiple sclerosis.

Abstract: The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.

Abstract: Disclosed are ingestible additives and ingestible supplements that are capable of promoting liver function, promoting liver health, or reducing alcoholic hepatopathy in a subject. The ingestible additive or supplement can include at least one essential amino acid, at least non-essential amino acid, at least one antioxidant, at least one lipotropic compound, at least one water-soluble vitamin, or at least one plant or extract thereof.

Abstract: The embodiments of the present invention provide herbal syrup comprising Nigella sativa (Nigella) seed extract and Zingiber officinale (ginger) root extract. The Nigella seeds and ginger roots are identified in a herbarium and confirmed. The Nigella seeds and ginger roots are cleaned and disinfected. After disinfection the Nigella seeds and ginger roots are grinded separately to obtain powder. The powders of Nigella seed and ginger root are treated in a percolator machine to extract thymoquinone and gingerol. The Nigella seed extract and ginger extract are mixed and herbal syrup is made for the patients with abnormal sperm parameters. The dosage of the herbal syrup is 7 ml. The syrup is administered daily during breakfast for 4 months. The sperm count increases gradually from 15 million/ml, 43 million/ml, 89 million/ml and 120 million/ml after four month of administration.

Abstract: The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells.

Abstract: The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.